▲ Peaking
Business
Why This Biotech Stock, With Its First FDA Approval, Just Crashed By Double Digits
Celcuity shares dropped by double digits despite receiving its first FDA approval for a breast cancer drug.
Celcuity
1 trends tracked about this subject — the full history, oldest to newest below.